Childhood mortality after a high dose of vitamin A in a high risk population

N M Daulaire1, E S Starbuck, R M Houston

  • 1International Center for the Prevention and Treatment of Major Childhood Disease (INTERCEPT), Hanover, New Hampshire 03755.

BMJ (Clinical Research Ed.)
|January 25, 1992
PubMed

Insights

High-dose vitamin A supplementation significantly reduced child mortality by 26% in communities with high malnutrition. This intervention was cost-effective and easily integrated into existing health programs, improving child survival rates.

Area of Science:

  • Public Health
  • Nutritional Epidemiology
  • International Health

Background:

  • High child mortality and malnutrition are prevalent in many low-income regions.
  • Vitamin A deficiency is a significant contributor to childhood illness and death.
  • Effective, scalable interventions are needed to improve child survival.

Purpose of the Study:

  • To evaluate the impact of a single high dose of vitamin A on child mortality in high-risk communities.
  • To assess the feasibility of integrating community-wide vitamin A supplementation into primary healthcare programs.

Main Methods:

  • An opportunistic controlled trial was conducted in Jumla district, Nepal.
  • 3786 children under 5 received a single high dose of vitamin A, while 3411 children in control subdistricts did not.
  • Mortality and causes of death were monitored for five months post-supplementation.

Main Results:

  • Supplemented children aged 1-59 months had a 26% lower risk of death (RR 0.74).
  • Mortality reduction was most pronounced in infants aged 6-11 months (RR 0.51).
  • Diarrheal disease mortality also decreased significantly (RR 0.65), with an estimated cost of $11 per death averted.

Conclusions:

  • Vitamin A supplementation plays a crucial role in enhancing child survival.
  • The vitamin A supplementation program was successfully integrated into existing community health services with minimal additional cost.
Abstract

Related Concept Videos

Teratogenicity01:07

Teratogenicity

The ability of a drug to produce structural deformations and functional abnormalities in the developing embryo or the fetus is called teratogenicity, and the drug producing this effect is known as a teratogen. Teratogenic effects include stillbirth, miscarriage, intrauterine growth restriction, and neurocognitive delay. A teratogen may affect the embryo at different stages of development, which is important in determining the type and extent of the damage. During blastocyst formation, the early...
Mutagenicity and Carcinogenicity01:25

Mutagenicity and Carcinogenicity

Mutagenicity and carcinogenicity refer to the ability of drugs to cause genetic defects and induce cancer, respectively. The International Agency for Research on Cancer (IARC) classifies agents into four groups based on their carcinogenic potential. Group 1 agents are known human carcinogens; group 2A agents are probably carcinogenic to humans; group 3 agents lack data to support their role in carcinogenesis; and group 4 includes agents for which data support that they are not likely to be...
Immunodeficiency Diseases01:25

Immunodeficiency Diseases

Immunodeficiency disorders are conditions in which the immune system's ability to fight infectious disease and cancer is compromised or entirely absent. The immune system comprises a complex network of cells, tissues, and organs that work together to protect the body from potentially harmful invaders. When this system is deficient or not functioning properly, it leaves the body susceptible to infections, diseases, or other complications.
There are three main causes of immunodeficiency disorders...
Pulmonary Tuberculosis I01:29

Pulmonary Tuberculosis I

Tuberculosis, often called TB, is a contagious illness primarily caused by Mycobacterium tuberculosis. It mainly affects the lung parenchyma but can also impact other body parts.
Causative Organism
The primary infectious agent causing tuberculosis is Mycobacterium tuberculosis, a slow-growing, acid-fast, aerobic rod that exhibits sensitivity to heat and ultraviolet light. Instances of Mycobacterium bovis and Mycobacterium avium contributing to the development of TB infection are rare.
Mode of...
Drug Dosing: Infants and Children01:29

Drug Dosing: Infants and Children

Pediatric patient dosages diverge from adults due to disparities in body surface area, total body water, and extracellular fluid per kilogram of body weight. The dosing regimen considers the variations in pharmacokinetics and pharmacology across distinct age groups, encompassing preterm newborns, infants, young children, older children, and adolescents. Calculation of pediatric patient doses is predicated on determining body surface area, which exhibits a superior correlation with the child's...